Skip to main content

Navigation group

Type at least 3 characters
29,924 articles

Articles

Correction

Published on 31 Jan 2025

Corrigendum: First-in-human phase 1 dose-escalation results with livmoniplimab, an antibody targeting the GARP: TGF-ß1 complex, as monotherapy and in combination with the anti–PD-1 antibody budigalimab in patients with advanced solid tumors

in Cancer Molecular Targets and Therapeutics

  • Toshio Shimizu
  • John Powderly
  • Albiruni Abdul Razak
  • Patricia LoRusso
  • Kathy D. Miller
  • Steven Kao
  • Sarah Kongpachith
  • Catherine Tribouley
  • Michelle Graham
  • Brian Stoll
Frontiers in Oncology
doi 10.3389/fonc.2024.1544394
  • 106 views